相关实验视频

Updated: Jun 21, 2026

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

免疫类型的,但不是遗传的变化重新分类了大多数早期T细胞前体急性淋巴细胞白血病的复发/耐药儿科病例

Irina Demina¹, Aya Dagestani¹, Aleksandra Borkovskaia¹

¹Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow 117998, Russia.

International journal of molecular sciences

|June 19, 2024

概括

复发的早期T细胞前体急性淋巴细胞白血病 (ETP-ALL) 通常表现为模两可的血统或急性髓性白血病 (AML) 现型. 遗传标记通常保持稳定,指导儿童ETP-ALL的治疗决策.

科学领域:

儿科血液瘤学
白血病研究研究白血病研究
分子诊断学分子诊断

背景情况:

早期T细胞前体急性淋巴细胞白血病 (ETP-ALL) 起源于多能原始细胞.
ETP-ALL白血病爆发可以表现出模两可的表型,使诊断复杂化,特别是在复发时.
了解复发特征对于优化儿科ETP-ALL治疗策略至关重要.

研究的目的:

为了调查复发儿科ETP-ALL的免疫表型变化.
分析复发性ETP-ALL的遗传特征和分类挑战.
为改善ETP-ALL复发的诊断和治疗决策提供见解.

主要方法:

在2017-2022年期间诊断出7518名急性白血病患者的综合分析.
使用了传统的免疫类型,胆型,FISH和下一代测序 (TCR谱,RT-PCR,RNA-seq).
对比了儿科ETP-ALL患者的初始诊断和复发样本.

主要成果:

在534例T细胞ALL病例中,有60例是ETP-ALL;10例 (16.7%) 复发.
大多数复发呈现为含糊血统的急性白血病 (n=5) 或急性髓性白血病 (AML) (n=4).
主要的遗传标记在很大程度上没有变化;一些复发表明多克隆种群或克隆TRD重新排列.

结论:

复发的ETP-ALL经常表现出改变的免疫表型,通常模仿AML或模两可的血统.
复发时稳定的遗传特征,尽管有表型变化,对于诊断很重要.
对复发性ETP-ALL的治疗决策应整合初始免疫类型和分子数据.

关键词:

在 ETP-ALL 中,所有免疫类型免疫类型线程交换机线程交换机线程交换机这是一个复发的复发.

更多相关视频

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

Author Spotlight: Identification and Isolation of Quiescent Leukemia Stem Cells from Zebrafish T-ALL

Author Spotlight: Identification and Isolation of Quiescent Leukemia Stem Cells from Zebrafish T-ALL

Published on: July 19, 2024

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...